Entasis Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Entasis Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014156
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Entasis Therapeutics Inc (Entasis) discovers and develops anti-infective products for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections, such as Acinetobacter baumannii; and ETX0914, a oral antibiotic for the treatment of uncomplicated gonorrhea. It provides drug discovery platform that concentrates on the development of antibacterials targeting serious gram-negative infections including pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis has developed robust clinical and pre-clinical pipeline of medicines. The company offers small-molecule programs to treat multidrug-resistant gram-negative infections. Entasis is headquartered in Waltham, Massachusetts, the US.

Entasis Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Entasis Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 11
Entasis Therapeutics Raises USD50 Million in Series B Financing 12
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 13
Partnerships 14
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 14
Entasis Therapeutics Inc – Key Competitors 15
Entasis Therapeutics Inc – Key Employees 16
Entasis Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Apr 10, 2017: Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer 18
Nov 29, 2016: Entasis Therapeutics appoints new board member 19
Nov 29, 2016: Entasis Therapeutics Names Greg Norden, Former Senior Vice President and Chief Financial Officer of Wyeth, to its Board of Directors 20
Product News 21
10/28/2016: Entasis Therapeutics to Present Data at IDWeek on ETX2514SUL, a Novel Drug Targeting Multidrug-Resistant Acinetobacter baumannii Infections 21
06/30/2017: Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas 22
06/07/2017: Entasis Therapeutics Presents Data on ETX2514 at ASM Microbe 2017 23
05/22/2017: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2017 24
05/22/2017: Entasis Therapeutics to Present Data on ETX1317 at ASM Microbe 2017 25
05/22/2017: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2017 26
Clinical Trials 27
Oct 26, 2016: Entasis Announces Initiation of Phase I Clinical Trial of ETX2514 27
Jun 28, 2016: Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Entasis Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Entasis Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 11
Entasis Therapeutics Raises USD50 Million in Series B Financing 12
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 13
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 14
Entasis Therapeutics Inc, Key Competitors 15
Entasis Therapeutics Inc, Key Employees 16

★海外企業調査レポート[Entasis Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vikas WSP Ltd (519307):企業の財務・戦略的SWOT分析
    Vikas WSP Ltd (519307) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Empire Co Ltd:企業の戦略・SWOT・財務情報
    Empire Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Empire Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Prothena Corp Plc (PRTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Prothena Corp Plc (Prothena) is a clinical biotechnology company, which discovers, develops and markets novel medicines that are indicated for the treatment of diseases associated with neuroscience and orphan diseases. The company develops monoclonal antibodies directed specifically at disea …
  • Ricerca Biosciences LLC-製薬・医療分野:企業M&A・提携分析
    Summary Ricerca Biosciences LLC (Ricerca), formerly Ricerca Inc, a subsidiary of Main Market Partners LLC, is a contract research organization that offers services to accelerate drug development. The organization's service portfolio includes drug safety and metabolism, chemical development, agrochem …
  • Lutronic Corp (085370):企業の財務・戦略的SWOT分析
    Lutronic Corp (085370) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Baxter International Inc.:企業の戦略・SWOT・財務情報
    Baxter International Inc. - Strategy, SWOT and Corporate Finance Report Summary Baxter International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Alstom SA (ALO):電力:M&Aディール及び事業提携情報
    Summary Alstom SA (Alstom) is a marketer and developer of transport systems. The company offers a wide range of solutions ranging from high-speed trains to metros and tramways including customized services such as maintenance and modernization, and infrastructure up to signaling solutions. It design …
  • Mineral Resources Ltd
    Mineral Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Mineral Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Kingsgate Consolidated Limited:企業の戦略・SWOT・財務情報
    Kingsgate Consolidated Limited - Strategy, SWOT and Corporate Finance Report Summary Kingsgate Consolidated Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • SerComm Corp (5388):企業の財務・戦略的SWOT分析
    SerComm Corp (5388) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Societe BIC (BB):企業の財務・戦略的SWOT分析
    Societe BIC (BB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • M. A. Mortenson Co:戦略・SWOT・企業財務分析
    M. A. Mortenson Co - Strategy, SWOT and Corporate Finance Report Summary M. A. Mortenson Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cogentix Medical Inc (CGNT):企業の財務・戦略的SWOT分析
    Summary Cogentix Medical Inc (Cogentix Medical), formerly Vision-Sciences Inc, is a medical device company that designs, develops, manufactures and markets fiberoptic and video endoscopy products. The company’s major products include PrimeSight endoscopy systems, Urgent PC neuromodulation system and …
  • CROS NT srl-製薬・医療分野:企業M&A・提携分析
    Summary CROS NT srl (CROS NT) is a contract research organization (CRO), which specializes in clinical data management, analysis, reporting and technologies. Its services include programming, analysis, medical writing, CROS academy training, methodology and clinical data management. Its outsourcing …
  • Health Care Service Corp:企業の戦略的SWOT分析
    Health Care Service Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Partner Reinsurance Asia Pte. Ltd.
    Partner Reinsurance Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Partner Reinsurance Asia Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • IDBI Bank Ltd:企業の戦略・SWOT・財務情報
    IDBI Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary IDBI Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Retrophin Inc (RTRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Retrophin Inc (Retrophin) is a biopharmaceutical company that discovers, develops, acquires and commercializes drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for various catastrophic diseases. Retrophin’s pipeline prod …
  • Cimarex Energy Co (XEC):企業の財務・戦略的SWOT分析
    Cimarex Energy Co (XEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Dragon Oil Plc:企業の戦略的SWOT分析
    Dragon Oil Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆